HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence.

AuthorsReena H Hemrajani, Kevin B Kim, Warren R Amos, David E Mann
JournalMelanoma research (Melanoma Res) Vol. 17 Issue 4 Pg. 257-9 (Aug 2007) ISSN: 0960-8931 [Print] England
PMID17625458 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Recombinant Proteins
  • sargramostim
  • Granulocyte-Macrophage Colony-Stimulating Factor
Topics
  • Antineoplastic Agents (therapeutic use)
  • Granulocyte-Macrophage Colony-Stimulating Factor (metabolism, therapeutic use)
  • Humans
  • Immune System
  • Immunotherapy (methods)
  • Male
  • Melanoma (drug therapy, pathology)
  • Middle Aged
  • Models, Biological
  • Neoplasm Metastasis
  • Recombinant Proteins
  • Remission Induction
  • Secondary Prevention
  • Skin Neoplasms (drug therapy, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: